Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China
RegulatoryapprovedYochanra®Positive
AI Analysis
Summary
TransThera Sciences' Yochanra® becomes the first drug independently developed in China to overcome acquired resistance to FGFR inhibitor therapy in cholangiocarcinoma patients, marking its global debut in the Chinese market.
Outcome Details
First drug independently developed in China to address FGFR inhibitor resistance; made global debut in China
Importance:8/10
Sentiment:
0.85
China approvalFGFR inhibitorcholangiocarcinomadrug resistancefirst-in-class
Related Companies
Read the original article
Published by PR Newswire Biotech on August 7, 2026 6:44 AM